Navigation Links
KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)
Date:6/24/2009

DURHAM, N.C., June 24 /PRNewswire/ -- KBI Biopharma, Inc. (KBI) announced today that it has started the process of performing cell line generation with Crucell's PER.C6(R) human cell line platform, pursuant to the Agreement announced by Crucell, The Netherlands, on May 6, 2009. Under that agreement, KBI joins the Vendor Network as a U.S.-based pre-approved cell line generation partner for licensees of the PER.C6(R) cell lines.

KBI is a leading biopharmaceutical contract services company providing fully integrated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. KBI, based in Durham, NC, applies cell line generation, extensive protein characterization, manufacturing process development and clinical biomanufacturing capabilities to accelerate and optimize its clients' drug development programs. This comprehensive and integrated suite of services enables clients to bring drugs to market faster and more efficiently. KBI is recognized for its track record in advancing its clients' drug programs by developing scalable, robust processes that result in more stable, active products.

Joseph McMahon, President and CEO of KBI Biopharma notes, "We recognize the significant market interest in and adoption of this technology and are very pleased to now offer cell line generation using the PER.C6(R) cell line." Mr. McMahon added, "Our KBI scientific team has extensive experience producing cell lines in microbial, insect and mammalian systems and are very pleased that Crucell and DSM have recognized our expertise by selecting KBI as a Partner for their Vendor Network."

KBI is now proud to offer the PER.C6(R) technology as part of its extensive capabilities in cell line development.

Other terms of the agreement were not disclosed.

About KBI Biopharma, Inc.

KBI Biopharma, located in Durham, NC, is a leading contract development organization for the biopharmaceutical industry, working with companies across the globe focused on protein-based products. KBI delivers expert and integrated biophysical and biochemical protein characterization, formulation and process development and cGMP manufacturing of recombinant protein Active Pharmaceutical Ingredients (API's). For additional information about KBI Biopharma please visit www.kbibiopharma.com.

PER.C6(R) technology

Crucell's PER.C6(R) technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins, including monoclonal antibodies. Compared to conventional production technologies, the strengths of PER.C6(R) technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions. By employing the PER.C6(R) human cell line with a proprietary process technology, a record yield of over 27 grams per liter in the production of IgG antibodies has been achieved.


'/>"/>
SOURCE KBI Biopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2020)... ... ... Vuja De Sciences (“Vuja De”), a biotechnology startup dedicated to developing cancer metastasis ... DVM, PhD, DACVIM (Onc), and Dr. Lee Helman, MD, to its Board of Directors. ... Chand and Lee as new directors. They will be of great help in advancing ...
(Date:1/7/2020)... MATEO, CA (PRWEB) , ... January 06, 2020 ... ... Smart Home Control, today announced its expansion into whole-home smart lighting with two ... Smart Dimmer Switch unlocks the ability for homeowners and homebuilders to affordably add ...
(Date:12/31/2019)... ... 2019 , ... Vici Health Sciences announces it ... Maryland. Emphasis will be in expanding capabilities in both oral and parenteral dosage ... well positioned to meet the growing demand for its pharmaceutical formulation and analytical ...
(Date:12/30/2019)... TOWNSHIP, N.J. (PRWEB) , ... December 30, 2019 ... ... of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device ... SIMS Version 1.11.19 21 CFR Part 11 compliant software program specific to the ...
Breaking Biology Technology:
(Date:1/23/2020)... ... January 23, 2020 , ... ... blood cells from stem cells. The red blood cells are made utilizing ... controlled conditions, for transfusion therapy and replaces the need for a human blood ...
(Date:1/22/2020)... ... January 21, 2020 , ... ... lead the company’s new Business Development Department. The move, which is part of ... been previously serving as the company’s Senior Vice President where he oversaw its ...
(Date:1/22/2020)... (PRWEB) , ... January 21, ... ... specializes in integrating cold chain operations, developing transport validation strategies, supporting global ... by both Inc. 5000 and the Houston Business Journal as a fastest ...
Breaking Biology News(10 mins):